| 摘要 |
Provided are 2-substituted 4,5-diaryl imidazoles, in particular compounds of Formula I wherein R1, R2, R3 and R4 are as defined, in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form, which have p38 MAP kinase (Mitogen Activated Protein Kinase) inhibiting activity. The compounds are used as pharmaceuticals for treating TNFa and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, such as osteoporosis; R1 is 4-pyridyl, which is optionally substituted with one or two substituents each of which is independently selected from C1-4alkyl, halogen, C1-4alkoxy, C1-4alkylthio, NR5R6, wherein R5 and R6 is each independently C1-4alkyl; R2 is phenyl, naphth-1-yl or naphth-2-yl, which is optionally substituted by up to 5 substituents; R3 is hydrogen, R4 is optionally substituted pyridyl; in free or pharmaceutically acceptable addition salts or physiologically-cleavable ester form provided that R2 is not phenyl substituted with a radical selected from alkylsulfonyl or aminosulfonyl.
|
